Loading…
Company provided a clinical update on December 17, 2025.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced on December 17, 2025, a clinical update on its ongoing Phase 2 study of NGC-Cap, a combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. The study involves 16 of 19 patients who have been treated with NGC-Cap, with a total of 20 patients planned for enrollment.
Patients received PCS6422 at a dose of 150 mg twice daily and capecitabine at a dose of 1,000 mg/m² twice daily. The treatment showed up to ten times less toxicity. Processa Pharmaceuticals has 2,040,800 shares in free float and 2,265,800 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.